Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NR80
UPID:
ARHG4_HUMAN
Alternative names:
APC-stimulated guanine nucleotide exchange factor 1
Alternative UPACC:
Q9NR80; Q9HDC6; Q9UPP0
Background:
Rho guanine nucleotide exchange factor 4 (RhoGEF4), also known as APC-stimulated guanine nucleotide exchange factor 1, plays a pivotal role in cellular processes by acting as a guanine nucleotide exchange factor for RHOA, RAC1, and CDC42 GTPases. Its interaction with APC influences RAC1 GEF activity, contributing to cell migration and E-cadherin-mediated cell-cell adhesion. RhoGEF4 is essential for MMP9 up-regulation through the JNK signaling pathway in colorectal tumor cells and is implicated in tumor angiogenesis, intestinal adenoma formation, and tumor progression.
Therapeutic significance:
Understanding the role of Rho guanine nucleotide exchange factor 4 could open doors to potential therapeutic strategies.